An interventional study of Strict glucose control in Diabetes Mellitus, Type 1 and Islet Transplantation, sponsored by Vancouver Coastal Health. Withdrawn at 1 site in Canada. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2015-04-01.
Sponsored by Vancouver Coastal Health · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 319 studies in Diabetes Mellitus, Type 1 with a site in Canada — 49 open to participants now, 61 under way, 15 of them phase 3. Diabetes Mellitus, Type 1 · Canada.
Among the 319 studies in Diabetes Mellitus, Type 1 with a site in Canada, this one is the 268th largest by enrollment of the 275 interventional ones that give a count, is one of 5 that started in 2011, is one of 99 with no phase, and was the 58th registered.
3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →49 of the 319 studies in Diabetes Mellitus, Type 1 with a site in Canada are open now. Recruiting first, the newest first:
Institut de Recherches Cliniques de Montreal · Sites in Canada
Ages 18+
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages 18–65
Kriya Therapeutics, Inc. · Sites in Canada, New Zealand
Ages 18–65
Institut de Recherches Cliniques de Montreal · Sites in Canada
Ages 18+ · Healthy volunteers
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada, Switzerland
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
319 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 35 · Phase 2 79 · Phase 3 70 · Phase 4 12
First in 1983; this study’s year is marked. 5 started in 2011.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 45 across the 275 interventional studies, 205 across the 44 observational. Of the 231 that completed or were terminated, 73 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
97 of 319 have an industry lead sponsor. The 10 most frequent:
Vancouver Coastal Health is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
Vancouver Coastal Health has 1 study filed under Diabetes Mellitus, Type 1 — fewer than ten, so there is no comparison to draw.
23 of the studies in Diabetes Mellitus, Type 1 with a site in Canada that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06962280Phase 3Eli Lilly and CompanyA Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06894784Phase 3McGill University Health Centre/Research Institute of the McGill University Health CentreA Clinical Trial to Evaluate The Effects of Semaglutide and Empagliflozin Combined to Automated Insulin Delivery on Diabetes Control in Adults Living With Type 1 Diabetes | 2027-01 |
| NCT07076199Phase 3Novo Nordisk A/SA Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes | 2027-01-25 |
| NCT05762107Zucara Therapeutics Inc.A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes | 2026-12 |
| NCT04963777University of CalgaryPrebiotics in Patients With Type 1 Diabetes | 2026-12-01 |
Add all 23 to your calendar (.ics) → With an account.
Among the 319 studies in Diabetes Mellitus, Type 1 with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Islet transplants for those with type 1 diabetes have enabled many to initially eliminate insulin, however, only a fraction of the transplanted cells typically survive and the functioning of these decrease over time. As a result, most patients will eventually require some insulin. Currently, the cause of this poor survival and decrease in function is not understood; although previous research has demonstrated that even a slightly elevated level of blood glucose can impair islet function. This study will determine if strict blood glucose control at the time of islet transplantation, when the cells are the most fragile, will improve the survival and functioning of transplanted islet cells three months after transplantation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: Strict glucose control
Blood glucose level to be maintained at 4-6 mmol/L at the time of islet transplantation until two weeks post-transplantation.
Islet cell function
Function will be assessed three months post-transplantation.
Time frame: Three months
The record gives a start of Sep 2011, a primary completion of Sep 2015 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in May 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Vancouver Coastal Health